A Phase 3 interventional study of Oral treprostinil in Pulmonary Hypertension Associated With HFpEF, sponsored by United Therapeutics. Terminated at 82 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-10-22.
Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing treprostinil in Hypertension, Pulmonary — 4 open to participants now, 4 under way, 1 of them phase 3. treprostinil · Hypertension, Pulmonary.
Among the 38 studies testing treprostinil in Hypertension, Pulmonary, this one is the 13th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2018, is one of 15 in phase 3, and was the 27th registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.
Browse Hypertension, Pulmonary studies →4 of the 38 studies testing treprostinil in Hypertension, Pulmonary are open now, in 12 countries. Recruiting first, the newest first:
Valley Health System · Sites in United States
Ages 18+
Liquidia Technologies, Inc. · Sites in United States, Australia, Austria and 9 more countries
Ages 18–80
Magdi H. Yacoub · Sites in Egypt
Ages 18+
University of California, San Diego
Ages 18+
By country, each count listing its studies:
treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 17 · Phase 4 9
First in 1998; this study’s year is marked. 3 started in 2018.
This study's enrollment of 48 is above the median of 35 across 650 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 32 across the 37 interventional studies. Of the 29 that completed or were terminated, 19 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 38 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
36 studies in Hypertension, Pulmonary by United Therapeutics: 4 open now, 4 under way, 2 of them phase 3. Of 28 finished, 21 (75%) have results posted.
Among the 36 studies in Hypertension, Pulmonary by United Therapeutics, this one is the 15th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2018, is one of 16 in phase 3, and was the 24th registered.
United Therapeutics’s Hypertension, Pulmonary studies by the year they started, since 1998.
1 of the studies testing treprostinil in Hypertension, Pulmonary that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07116681University of California, San DiegoEffects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension | 2027-07-01 |
Add it to your calendar (.ics) → With an account.
Among the 38 studies testing treprostinil in Hypertension, Pulmonary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among United Therapeutics’s 36 in Hypertension, Pulmonary:
This tab as a report to print or save as PDF → With an account.
This was an open-label study to evaluate the safety of continued therapy with oral treprostinil in subjects who completed Study TDE-HF-301. This study provided long-term, open-label data regarding the effect of continued long-term oral treprostinil therapy for the treatment of pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (HFpEF). Subject visits occurred at Baseline, Weeks 6, 12, 18, 24, and every 12 weeks thereafter until either oral treprostinil was commercially available to treat PH associated with HFpEF or the study was discontinued by the Sponsor.
The Sponsor terminated Studies TDE-HF-301 and TDE-HF-302 on 14 October 2019 due to slow enrollment. Safety data from the final subject in Study TDE-HF-302 were recorded on 02 March 2020. Due to the lower than expected number of subjects enrolled, the planned secondary efficacy-related endpoints were not analyzed.
Study TDE-HF-302 was a multicenter, open-label study in subjects participating and completing all required visits for Study TDE-HF-301. This study assessed the long-term safety of oral treprostinil in subjects with PH associated with HFpEF.
Subjects received oral treprostinil as 0.125-, 0.25-, 1-, and 2.5-mg sustained-release tablets. For subjects who were randomly allocated to receive oral treprostinil in Study TDE-HF-301, the initial dose of oral treprostinil was the same as the final dose in Study TDE-HF-301. Subjects randomly allocated to receive placebo in Study TDE-HF-301 were administered the initial dose of oral treprostinil at 0.125 mg 3 times daily (TID). Dose increases could occur in 0.125-mg increments every 72 hours at the discretion of the Investigator up to 6 mg TID, the maximum allowable dose determined by the Data Monitoring Committee during Study TDE-HF-301. Doses of study drug were to be increased in the absence of dose-limiting drug-related adverse events (AEs) to ensure that each subject received the optimal dose throughout the study. Subjects returned for visits at Weeks 6, 12, 18, and 24, and every 12 weeks thereafter. Subjects who terminated the study early were asked to return to the study center for a final evaluation.
Safety assessments consisted of AEs, clinical laboratory parameters, and clinical assessment of heart failure signs and symptoms.
Due to the lower than expected number of subjects enrolled, the planned secondary efficacy-related endpoints were not analyzed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Sustained-release tablets for TID administration
Drug: Oral treprostinil
Sustained-release oral tablets for TID administration
Also known as: Treprostinil diethanolamine, Treprostinil diolamine
Long-term Safety of Oral Treprostinil in Subjects With PH Associated With HFpEF for Subjects Who Completed Study TDE-HF-301
The primary objective of this study was to evaluate the long-term safety of oral treprostinil in subjects with PH associated with HFpEF for subjects who completed Study TDE-HF-301. The number of subjects with adverse events during the study is reported as the primary outcome measure, which was the only outcome measurement reported for this Sponsor-terminated study.
Time frame: Baseline through study completion, up to approximately 25 months
| Milestone | Oral Treprostinil |
|---|---|
| Started | 48 |
| Completed | 0 |
| Not completed | 48 |
| Withdrew: Death | 1 |
| Withdrew: Progressive disease | 2 |
| Withdrew: Adverse event | 2 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Study terminated by sponsor | 39 |
The primary objective of this study was to evaluate the long-term safety of oral treprostinil in subjects with PH associated with HFpEF for subjects who completed Study TDE-HF-301. The number of subjects with adverse events during the study is reported as the primary outcome measure, which was the only outcome measurement reported for this Sponsor-terminated study.
| Participants | Oral Treprostinil |
|---|---|
| Long-term Safety of Oral Treprostinil in Subjects With PH Associated With HFpEF for Subjects Who Completed Study TDE-HF-301 | 47 |
Collected over The study duration was 25 months overall. The study was discontinued by the Sponsor on 14 October 2019 due to slow enrollment in the parent study, TDE-HF-301.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oral Treprostinil | 1/48 (2.1%) | 19/48 (39.6%) | 47/48 (97.9%) |
| Event | Oral Treprostinil |
|---|---|
| Acute kidney injuryRenal and urinary disorders | 4/48 |
| Cardiac failureCardiac disorders | 3/48 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 2/48 |
| Cardiac failure acuteCardiac disorders | 2/48 |
| Cardiac failure congestiveCardiac disorders | 2/48 |
| HypokalaemiaMetabolism and nutrition disorders | 2/48 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/48 |
| PneumoniaInfections and infestations | 2/48 |
| Atrial fibrillationCardiac disorders | 1/48 |
| AzotaemiaRenal and urinary disorders | 1/48 |
| Event | Oral Treprostinil |
|---|---|
| HeadacheNervous system disorders | 31/48 |
| DiarrhoeaGastrointestinal disorders | 26/48 |
| NauseaGastrointestinal disorders | 17/48 |
| FatigueGeneral disorders | 15/48 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 13/48 |
| DizzinessNervous system disorders | 9/48 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 9/48 |
| Oedema peripheralGeneral disorders | 9/48 |
| Back painMusculoskeletal and connective tissue disorders | 8/48 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/48 |
All Subjects
| Age, Continuous(years) | Oral Treprostinil |
|---|---|
| Median | 76.0 (46 to 85) |
| Sex: Female, Male(Participants) | Oral Treprostinil |
|---|---|
| Female | 35 |
| Male | 13 |
| Ethnicity (NIH/OMB)(Participants) | Oral Treprostinil |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 47 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Oral Treprostinil |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 5 |
| White | 43 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2018 to primary completion in Mar 2020, 25 months.
Results were first posted in Oct 2020, 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil